Biosimilars: A Physician Perspective

To say the environment around biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the biosimilar market by taking a big picture, macro assessment of the regulatory, clinical development, and commercialization issues. Industry Standard Research (ISR) took a focused approach to answering a few pointed questions around the potential prescribing of biosimilars. We took this approach because of the fluid nature of the environment. We took this approach because regardless of the nascent legislation recently enacted in the United States, or the forthcoming plan from the FDA, and the relative low adoption of biosimilars in Europe; we believe that physicians/ prescribers will be at the strategic center of biosimilar success or failure.